31 Oct 2016 Date | | - Cons. EPS | - EPS |
31 Jul 2016 Date | | - Cons. EPS | - EPS |
30 Apr 2016 Date | | - Cons. EPS | - EPS |
31 Jan 2016 Date | | - Cons. EPS | - EPS |
31 Oct 2015 Date | | - Cons. EPS | - EPS |
31 Oct 2016 Date | | - Cons. EPS | - EPS |
31 Jul 2016 Date | | - Cons. EPS | - EPS |
30 Apr 2016 Date | | - Cons. EPS | - EPS |
31 Jan 2016 Date | | - Cons. EPS | - EPS |
31 Oct 2015 Date | | - Cons. EPS | - EPS |
Medical Devices Industry | Healthcare Sector | Ms. Christine M. Farrell CEO | OTCQB Exchange | US67612C1027 ISIN |
US Country | 6 Employees | - Last Dividend | - Last Split | - IPO Date |
Odyssey Health, Inc. is a medical company that is dedicated to the development and commercialization of innovative medical products. Initially known as Odyssey Group International, Inc., the company underwent a rebranding to better align with its mission and aims. Since its incorporation in 2014, Odyssey Health, Inc. has positioned itself at the forefront of medical advancement, focusing on delivering groundbreaking solutions to the healthcare industry. With its headquarters in Las Vegas, Nevada, the company leverages its strategic location and resources to push the boundaries of medical research and product development.
A state-of-the-art heart monitoring and screening device developed by Odyssey Health, Inc., CardioMap stands out for its advanced technology designed to improve heart health and diagnostics. This product underscores the company’s commitment to combating cardiovascular diseases through innovative solutions.
With a focus on emergency medical solutions, Odyssey Health, Inc. has developed Save A Life, a line of choking rescue devices intended for both professional healthcare settings and personal use. These devices reflect the company's dedication to providing simple, yet effective tools for critical situations, potentially saving lives in choking emergencies.
The development of ONP-001 and ONP-002 neurosteroid drug compounds showcases Odyssey Health, Inc.'s commitment to addressing concussions and rare brain disorders. These compounds are at the forefront of the company's research efforts, aiming to offer novel treatments that make a significant difference in the field of neurology and brain health.